A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 7, Issue 1, 2012, Pages 196-202

  Spigel, David R ^a,b   Hainsworth, John D ^a,b   Shipley, Dianna L ^b   Ervin, Thomas J ^c   Kohler, Peter C ^d   Lubiner, Eric T ^c   Peyton, James D ^b   Waterhouse, David M ^e   Burris, Howard A ^a,b   Greco, F Anthony ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Florida Cancer Specialists   (United States)

^d MUNSON MEDICAL CENTER   (United States)

^e Oncology Hematology Care Inc   (United States)

Author keywords

Bevacizumab; Elderly; Non small cell lung cancer; Pemetrexed

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CREATININE; CYANOCOBALAMIN; ERLOTINIB; FOLIC ACID; GEFITINIB; GEMCITABINE; PEMETREXED;

ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CAUSE OF DEATH; CELLULITIS; CONTROLLED STUDY; CREATININE CLEARANCE; DEHYDRATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG SAFETY; DYSPNEA; ELDERLY CARE; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERTENSION; HYPONATREMIA; INFECTION; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEPSIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT DURATION;

EID: 84655163441     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182307efe     Document Type: Article

References (32)

1. Davidoff AJ, Tang M, Seal B, et al. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2191-2197.
2. Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: An analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007;25:5570-5577.
3. Gridelli C, Langer C, Maione P, et al. Lung cancer in the elderly. J Clin Oncol 2007;25:1898-1907. (Pubitemid 46854424)
4. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-2067. (Pubitemid 30035956)
5. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003;21: 1383-1389. (Pubitemid 46606420)
6. Yee KW, Pater JL, Pho L, et al. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol 2003;21: 1618-1623. (Pubitemid 46594117)
7. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 2003;1(4 Suppl 2):18-24.
8. Repetto L, Audisio RA. Elderly patients have become the leading drug consumers: it's high time to properly evaluate new drugs within the real targeted population. J Clin Oncol 2006;24:e62-e63.
9. Gronberg BH, Bremnes RM, Flotten O, et al. Phase III Study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217-3224.
10. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
11. Rossi A, Ricciardi S, Maione P, et al. Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer 2009;66:141-149.
12. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
13. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase iii trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597. (Pubitemid 41079796)
14. Blakely LJ, Schwartzberg L, Keaton M, et al. A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer 2009;66:97-102.
15. Dudek AZ, Larson T, McCleod MJ, et al. Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer. J Thorac Oncol 2008;3:394-399. (Pubitemid 351489480)
16. Peacock NW, Spigel DR, Hainsworth JD, et al. A phase II trial of biweekly pemetrexed (P) and gemcitabine (G) in the first-line treatment (tx) of patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006;24(18 Suppl):17054.
17. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550. (Pubitemid 44917502)
18. Ramalingam SS, Dahlberg SE, Langer CJ, et al; Eastern Cooperative Oncology Group. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26:60-65.
19. Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
20. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
21. Lang K, Marciniak MD, Faries D, et al. Trends and predictors of first-line chemotherapy use among elderly patients with advanced nonsmall cell lung cancer in the United States. Lung Cancer 2009;63:264-270.
22. Ramsey SD, Howlader N, Etzioni RD, et al. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: Evidence from surveillance, epidemiology and end results-medicare. J Clin Oncol 2004;22:4971-4978. (Pubitemid 46638623)
23. Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest 2000;117:1239-1246. (Pubitemid 30321574)
24. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 2005;23:3112-3124. (Pubitemid 46224135)
25. Kornblith AB, Kemeny M, Peterson BL, et al. Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 2002;95:989-996. (Pubitemid 34925347)
26. Earle CC, Tsai JS, Gelber RD, et al. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol 2001;19:1064-1070. (Pubitemid 32176282)
27. Elderly Lung Cancer Vinorelbine Italian Study Group T. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
28. Lilenbaum RC, Herndon JE II, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005;23:190-196. (Pubitemid 41702638)
29. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-6266.
30. Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009;27:3284-3289.
31. Quoix EA, Oster J, Westeel V, et al. Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2010;28(18 Suppl):2.
32. A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer. U.S. National Institutes of Health; 2010. Available at: http://clinicaltrials.gov/ct2/show/ NCT00762034?term- paclitaxel